Investors Buy Large Volume of Medtronic Put Options (NYSE:MDT)

Medtronic PLC (NYSE:MDT) was the recipient of some unusual options trading on Thursday. Stock investors bought 24,238 put options on the stock. This is an increase of 45% compared to the average daily volume of 16,739 put options.

Insider Buying and Selling

In other Medtronic news, EVP Harry Kiil sold 1,483 shares of the firm’s stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $93.65, for a total value of $138,882.95. Following the completion of the transaction, the executive vice president directly owned 42,186 shares in the company, valued at $3,950,718.90. This trade represents a 3.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.27% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in MDT. WCM Investment Management LLC acquired a new stake in shares of Medtronic during the 1st quarter valued at $965,922,000. Capital Research Global Investors boosted its position in Medtronic by 12.6% during the 4th quarter. Capital Research Global Investors now owns 34,573,163 shares of the medical technology company’s stock worth $3,321,101,000 after buying an additional 3,880,174 shares during the period. First Eagle Investment Management LLC increased its position in Medtronic by 37.2% in the 2nd quarter. First Eagle Investment Management LLC now owns 13,783,983 shares of the medical technology company’s stock valued at $1,078,321,000 after acquiring an additional 3,739,288 shares during the period. Cullen Capital Management LLC bought a new position in shares of Medtronic during the second quarter valued at $202,764,000. Finally, Arrowstreet Capital Limited Partnership grew its stake in shares of Medtronic by 74.3% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 4,236,247 shares of the medical technology company’s stock worth $406,934,000 after purchasing an additional 1,805,524 shares during the last quarter. Institutional investors own 82.06% of the company’s stock.

Wall Street Analyst Weigh In

MDT has been the subject of several analyst reports. UBS Group raised their target price on shares of Medtronic from $100.00 to $110.00 and gave the company a “buy” rating in a research note on Thursday, September 3rd. Leerink Partners dropped their target price on shares of Medtronic from $117.00 to $104.00 and set an “outperform” rating on the stock in a report on Thursday, June 4th. Truist Financial reiterated a “hold” rating and set a $99.00 target price (up from $86.00) on shares of Medtronic in a research note on Wednesday, September 2nd. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $118.00 price target on shares of Medtronic in a report on Wednesday, September 2nd. Finally, Piper Sandler restated a “neutral” rating on shares of Medtronic in a research note on Monday, August 10th. Nineteen investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $103.92.

Medtronic News Roundup

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Analyst support: TD Cowen reaffirmed its “Buy” rating and set a $110 price target, implying substantial upside from recent levels. The endorsement may reinforce the view that Medtronic’s valuation is attractive after its recent weakness. Medtronic Earns Buy Rating from TD Cowen
• Positive Sentiment: New growth opportunities: Medtronic received FDA Breakthrough Device designation for a below-the-knee drug-coated balloon, potentially accelerating development and regulatory discussions for a device aimed at treating peripheral artery disease. Medtronic Receives Breakthrough Designation
• Positive Sentiment: Reimbursement progress: The American Medical Association approved Category I CPT codes for Medtronic’s Altaviva urinary incontinence device and Symplicity Spyral renal-denervation system. The codes take effect in January 2028 and could improve physician adoption and reimbursement visibility for these long-term growth products. Medtronic Receives Category I CPT Code Approvals
• Positive Sentiment: Cardiac and robotic-surgery expansion: FDA and European regulatory clearances for Affera cardiac-mapping software, PulseSelect software, and a LigaSure instrument for the Hugo robotic-surgery system broaden Medtronic’s competitive product portfolio. Medtronic Announces Regulatory Milestones
• Neutral Sentiment: Medtronic’s latest quarter exceeded analyst expectations, with $1.45 in EPS and $9.76 billion in revenue, but investors continue to assess whether projected growth can overcome competitive and execution concerns.
• Negative Sentiment: Unusually heavy put-option activity—24,238 puts purchased, roughly 45% above average—signals increased near-term hedging or bearish speculation. Separate analysis also noted the stock was down 6.4% since the latest earnings report, indicating lingering investor concerns despite the earnings beat.

Medtronic Stock Performance

NYSE:MDT opened at $86.41 on Friday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.54 and a current ratio of 2.07. Medtronic has a fifty-two week low of $73.31 and a fifty-two week high of $106.33. The company has a market cap of $110.53 billion, a price-to-earnings ratio of 21.28, a PEG ratio of 1.97 and a beta of 0.55. The stock has a fifty day moving average price of $90.08 and a 200-day moving average price of $84.78.

Medtronic (NYSE:MDT) last issued its earnings results on Tuesday, September 1st. The medical technology company reported $1.45 EPS for the quarter, beating the consensus estimate of $1.39 by $0.06. The company had revenue of $9.76 billion during the quarter, compared to analysts’ expectations of $9.55 billion. Medtronic had a net margin of 13.93% and a return on equity of 14.78%. The business’s revenue for the quarter was up 13.7% compared to the same quarter last year. During the same period in the previous year, the company earned $1.26 EPS. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. As a group, equities analysts anticipate that Medtronic will post 5.98 EPS for the current fiscal year.

Medtronic Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 16th. Stockholders of record on Friday, September 25th will be issued a dividend of $0.72 per share. The ex-dividend date of this dividend is Friday, September 25th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 3.3%. Medtronic’s payout ratio is 70.94%.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures devices, therapies and healthcare solutions for treating chronic and acute conditions. Its products are used in areas including cardiac and vascular care, neuroscience, medical and surgical procedures, and diabetes management.

The company’s portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, stents and other cardiovascular products; neuromodulation systems, deep-brain stimulation devices and spinal technologies; surgical instruments, robotic-assisted surgery systems and gastrointestinal diagnostic tools; and insulin pumps and related diabetes technologies.

Medtronic traces its origins to 1949, when Earl Bakken and Palmer Hermundslie founded the company in Minneapolis, Minnesota.